Skip to Content
Merck
CN
  • Establishment of the first newborn screening program in the People's Democratic Republic of Laos.

Establishment of the first newborn screening program in the People's Democratic Republic of Laos.

Journal of tropical pediatrics (2012-10-30)
Thomas Hoehn, Zoltan Lukacs, Maren Stehn, Ertan Mayatepek, Kedsatha Philavanh, Saysanasongkham Bounnack
ABSTRACT

The People's Democratic Republic of Laos belongs to the minority of countries worldwide without an established newborn bloodspot screening (NBS) system. In 2008, we initiated a pilot project of a neonatal screening system in the delivery suites of the Laotian capital, Vientiane. Samples were analysed for thyrotropin-stimulating hormone and 17-hydroxyprogesterone. Altogether 11 362 samples were taken; an initially high recall rate dropped eventually to just above 4%. Two cases of hypothyroidism and one case of congenital adrenal hyperplasia were identified and received timely treatment. In summary, we have demonstrated the feasibility of establishing an NBS system in a low-resource setting as prevalent in Laos. Obstacles for the establishment of a general NBS covering the whole country include the question of financial cover, treatment costs, and adequate teaching and supervision of technicians and doctors.

MATERIALS
Product Number
Brand
Product Description

Supelco
17α-Hydroxyprogesterone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®